American College of Cardiology Meeting In Brief: Warner-Lambert's Accupril
Executive Summary
Warner-Lambert's Accupril: Six-month treatment with Accupril (quinapril) improves endothelial function, an early marker of coronary atherosclerosis, in patients with established coronary disease and abnormal responses to acetylcholine, according to results from the Trial on Reversing Endothelial Dysfunction (TREND), presented March 24. In 129 patients undergoing PTCA randomized to 40 mg quinapril daily or placebo, the mean percent change in acetylcholine-induced diameter of the target coronary segment at six months was a 12.1% increase for quinapril and a .8% decrease for placebo (p=.002) in patients with 10-4 m diameters...